AstraZeneca’s MEDI8897 Receives FDA’s Breakthrough Therapy Designation (BTD) & EMA’s PRIME Designation for Lower Respiratory Tract Infection (LRTI) in Infants

 AstraZeneca’s MEDI8897 Receives FDA’s Breakthrough Therapy Designation (BTD) & EMA’s PRIME Designation for Lower Respiratory Tract Infection (LRTI) in Infants

AstraZeneca’s MEDI8897 Receives FDA’s Breakthrough Therapy Designation (BTD) & EMA’s PRIME Designation for Lower Respiratory Tract Infection (LRTI) in Infants

Shots:

  • The FDA’s BT & EMA’s PRIME designation is based on P-IIb trial results assessing MEDI8897 in patients with LTRI caused by respiratory syncytial virus (RSV) in premature infants @150 days
  • The P-IIb study resulted in meeting its 1EPs with reduction in the incidence of medically-attended LRTI
  • MEDI8897 is an extended half-life RSV F mAb, used for prevention of LRTI administered as a single dose within 5months and has received FDA’s FT designation in Mar,2015. In Mar, 2017 AstraZeneca and Sanofi Pasteur collaborated to jointly commercialize MEDI8897

Click here  Click here read full press release/ article | Ref: AstraZeneca | Image: The Hindu Business Line

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post